

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 22862-0003US1	Application No. 10/598,486
	Applicant Yu et al.		
	Filing Date August 31, 2006	Group Art Unit 1644	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	2004/0057935	03/25/2004	Yu et al.			
	2	2007/0020297	01/25/2007	Wheeler et al.			
	3	2008/0206286	08/28/2008	Yu			
	4	2008/0311141	12/18/2008	Yu et al.			
	5	2008/0311142	12/18/2008	Yu et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	6	WO 00/38730	07/06/2000	WIPO				
	7	WO 03/038430	05/08/2003	WIPO			Abstract	
	8	WO 2005/043155	05/12/2005	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	9	ALBERT et al., "Dendritic cell maturation is required for the cross-tolerization of CD8+T cells," Nat. Immunol, 2:1010-17 (2001)
	10	CHEN et al., "Colon cancer cells with high invasive potential are susceptible to induction of apoptosis by a selective COX-2 inhibitor", Cancer Science, 94:253-258 (2003)
	11	CORINTI et al., "Regulatory activity of autocrine IL-10 on dendritic cell functions," J. Immunol., 166:4312-18 (2001)
	12	DOVEDI et al., "Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma," Eur. Urol., 54:621-630 (2008)
	13	DOVEDI et al., "Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus calmette-guerin immunotherapy for bladder cancer," J. Urol., 174:332-337 (2005)
	14	EBERHART et al., "Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas," Gastroenterology, 107:1183-88 (1994)
	15	FERRANDINA et al., "Celecoxib modulates the expression of cyclooxygenase-2, Ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study", Clinical Cancer Research, 9:1324-31 (2003)
	16	GATZA et al., "Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma", Journal of Immunology, 169:5227-35 (2002)
	17	GRUBBS et al., "Celecoxib inhibits N-Butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female fischer-344 rats", Cancer Research 60:5599-5602
	18	HAAS et al., "Cyclooxygenase-2 inhibition augments the efficacy of a cancer vaccine," Clin. Cancer Res., 12:214-222 (2006)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 22862-0003US1	Application No. 10/598,486
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Yu et al.	
		Filing Date August 31, 2006	Group Art Unit 1644

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	19	HAHN et al., "Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer," Int. J. Cancer, 118:2220-31 (2006)
	20	JOKI et al., "Expression of Cyclooxygenase 2 (COX-2) in Human Glioma and in Vitro Inhibition by a Specific COX-2 Inhibitor, NS-398," Cancer Res., 60:4926-31 (2000)
	21	KALINSKI et al., "Prostaglandin E2 induces the final maturation of IL-12 deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation," J. Immunol, 161:2804-09 (1998)
	22	KIERTSCHER et al., "Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells," J. Immunol, 164:1269-76 (2000)
	23	KOKOGLU et al., "Prostaglandin E2 levels in human brain tumor tissues and arachidonic acid levels in the plasma membrane of human brain tumors," Cancer Lett., 132:17-21 (1998)
	24	KUPPNER et al., "Influence of PGE2- and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2-activated lymphocytes," J. Neurosurg, 72:619-625 (1990)
	25	MOHAMMED et al., "Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma 9TCC of the urinary bladder," Cancer Res., 59:5647-50 (1999)
	26	PIRTSKHALAISHVILI et al., "Cytokine-mediated protection of human dendritic cells from prostate cancer induced apoptosis is regulated by the Bcl-2 family of proteins," Br. J. Cancer, 83:506-513 (2000)
	27	SAWAMURA et al., "In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes," J. Neurooncol, 9:125-130 (2000)
	28	SHENG et al., "Inhibition of Human Color Cancer Cell Growth by Selective Inhibition of Cyclooxygenase-2", The Journal of Clinical Investigation, 99:2254-59 (1997)
	29	SHONO et al., "Cyclooxygenase-2 Expression in Human Gliomas: Prognostic Significance and Molecular Correlations," Cancer Research, 61:4375-81 (2001)
	30	TOOMEY et al., "Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma," Vaccine, 26:3540-49 (2008)
	31	WHITTAKER et al., "Autoregulation of human monocyte-derived dendritic cell maturation and IL-12 production by cyclooxygenase-2 mediated prostanoid production," J. Immunol., 165:4298-4304 (2000)
	32	WOLFF et al., "Expression of cyclooxygenase-2 in human lung carcinoma," Cancer Res., 58:4997-5001 (1998)
	33	EUROPEAN EXAMINER GABRIELA GREIF, Communication for Application No. EP 04809859.4, dated 10/31/2008, 4 pages
	34	JAPANESE EXAMINER HIROTOSHI YOKOI, Notice of Reasons for Rejection for Application No. 2006-534233, dated June 2, 2009, 12 pages (with translation)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	